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Background: Endothelial function is disrupted during percutaneous and surgical procedures, which can increase the risk of adverse cardiovascular 
events. Some evidence suggests that statins improve endothelial function, but their impact on clinical outcomes in patients undergoing invasive 
procedures is not completely understood.
Methods: We conducted a search of the Medline, Cochrane, and Clinicaltrials.gov databases from their inception to September 2009 for trials 
of human patients undergoing invasive procedures who were randomized to statin therapy versus control. No language restriction was used. To be 
included, studies must have reported clinical outcomes and initiated the study drug either pre-procedurally or during the index hospitalization. 
Studies of transplant patients were excluded. Data extraction was completed by the authors independently and discrepancies resolved by consensus. 
We calculated the cumulative incidence of selected outcomes and generated risk ratios for each of the outcomes using a random effects model.
Results: 12% of screened studies (39 of 270) were included, summarizing data from 14,441 patients. The use of pre-procedural statins 
significantly reduced post-procedural myocardial infarction in both surgical (3.7% versus 6.3%, RR = 0.50 [95% CI 0.32-0.80, p = 0.004]); and 
percutaneous patient populations (7.0% versus 11.1%, RR = 0.62 [95% CI 0.45-0.85, p = 0.003]). Post-surgical atrial fibrillation was significantly 
reduced (20.1% versus 37.6% RR 0.56 [95% CI 0.44-0.72, p<0.0001]). Among percutaneous patients, the use of peri-procedural statins also 
reduced long-term, all-cause mortality (1.7% versus 2.3%, RR 0.75 [95% CI 0.58-0.96, p=0.023]), unstable angina (3.9% versus 5.7%, RR = 0.71 
[95% CI 0.56-0.89, p=0.003]) and urgent revascularization (13.0% versus 15.1%, RR 0.86 [95% CI 0.78-0.95, p=0.003]).
Conclusion: Pre-procedural statins reduce the risk of atrial fibrillation after surgery and myocardial infarction after both surgical and percutaneous 
procedures. Patients undergoing percutaneous procedures suffered less unstable angina, urgent revascularization and all-cause mortality over the 
long term.
